RU2010119929A - Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины - Google Patents

Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины Download PDF

Info

Publication number
RU2010119929A
RU2010119929A RU2010119929/15A RU2010119929A RU2010119929A RU 2010119929 A RU2010119929 A RU 2010119929A RU 2010119929/15 A RU2010119929/15 A RU 2010119929/15A RU 2010119929 A RU2010119929 A RU 2010119929A RU 2010119929 A RU2010119929 A RU 2010119929A
Authority
RU
Russia
Prior art keywords
group
pharmaceutically acceptable
alkyl
hydrogen
active substance
Prior art date
Application number
RU2010119929/15A
Other languages
English (en)
Russian (ru)
Inventor
Рудольф ШРЕДЕР (DE)
Рудольф Шредер
Танья ХАЙТЕРМАНН (DE)
Танья Хайтерманн
Original Assignee
Эбботт Гмбх Унд Ко.Кг (De)
Эбботт Гмбх Унд Ко.Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Гмбх Унд Ко.Кг (De), Эбботт Гмбх Унд Ко.Кг filed Critical Эбботт Гмбх Унд Ко.Кг (De)
Publication of RU2010119929A publication Critical patent/RU2010119929A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2010119929/15A 2007-10-19 2008-10-17 Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины RU2010119929A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99961807P 2007-10-19 2007-10-19
US60/999,618 2007-10-19

Publications (1)

Publication Number Publication Date
RU2010119929A true RU2010119929A (ru) 2011-11-27

Family

ID=40089463

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010119929/15A RU2010119929A (ru) 2007-10-19 2008-10-17 Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины

Country Status (18)

Country Link
EP (1) EP2197425A2 (fr)
JP (1) JP2011500649A (fr)
KR (1) KR20100087170A (fr)
CN (1) CN101827584A (fr)
AU (1) AU2008313622A1 (fr)
BR (1) BRPI0818340A2 (fr)
CA (1) CA2699301A1 (fr)
CO (1) CO6270206A2 (fr)
CR (1) CR11442A (fr)
DO (1) DOP2010000117A (fr)
EC (1) ECSP10010183A (fr)
GT (1) GT201000102A (fr)
MX (1) MX2010004291A (fr)
PA (1) PA8800101A1 (fr)
RU (1) RU2010119929A (fr)
UA (1) UA100865C2 (fr)
WO (1) WO2009050291A2 (fr)
ZA (1) ZA201002095B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100176A2 (fr) * 2008-02-07 2009-08-13 Abbott Laboratories Forme pharmaceutique pour administration orale d’un inhibiteur de tyrosine kinase
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
MX2012014387A (es) * 2010-06-09 2013-05-01 Abbvie Inc Dispersiones solidas que contienen inhibidores de cinasa.
CA2855243C (fr) 2011-11-11 2020-04-14 Novartis Ag Procede de traitement d'une maladie proliferative
LT2782557T (lt) * 2011-11-23 2018-12-27 Array Biopharma, Inc. Farmacinės kompozicijos
WO2014003677A1 (fr) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Compositions pharmaceutiques comprenant des particules de dispersion solide contenant du tadalafil
WO2014003678A1 (fr) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Compositions pharmaceutiques comprenant de l'ambrisentan et des particules de dispersion solide contenant du tadalafil

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070104780A1 (en) * 2005-10-25 2007-05-10 Lipari John M Formulation comprising a drug of low water solubility and method of use thereof
WO2007066189A2 (fr) * 2005-12-09 2007-06-14 Pfizer Products Inc. Sels, promedicaments et formulations de 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-uree
EP2089003A1 (fr) * 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Forme de dosage pharmaceutique pour l'administration orale d'un inhibiteur de la tyrosine kinase

Also Published As

Publication number Publication date
DOP2010000117A (es) 2010-05-15
WO2009050291A2 (fr) 2009-04-23
BRPI0818340A2 (pt) 2015-04-22
UA100865C2 (ru) 2013-02-11
ZA201002095B (en) 2011-11-30
CA2699301A1 (fr) 2009-04-23
PA8800101A1 (es) 2009-05-15
JP2011500649A (ja) 2011-01-06
EP2197425A2 (fr) 2010-06-23
CO6270206A2 (es) 2011-04-20
CR11442A (es) 2010-09-06
CN101827584A (zh) 2010-09-08
WO2009050291A3 (fr) 2010-04-08
AU2008313622A1 (en) 2009-04-23
KR20100087170A (ko) 2010-08-03
MX2010004291A (es) 2010-08-02
GT201000102A (es) 2012-03-12
ECSP10010183A (es) 2010-06-29

Similar Documents

Publication Publication Date Title
RU2010119929A (ru) Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины
Ilevbare et al. Understanding Polymer Properties Important for Crystal Growth Inhibition Impact of Chemically Diverse Polymers on Solution Crystal Growth of Ritonavir
RU2010119924A (ru) Продукт твердой дисперсии, содержащей соединение на основе n-арилмочевины
AR070349A1 (es) Forma de dosificacion farmaceutica para administracion oral de inhibidor de tirosina quinasa
RU2014144001A (ru) Мягкие жевательные фармацевтические продукты
RU2011103085A (ru) Фармацевтическая дозированная форма, содержащая полимерную композицию-носитель
CY1110037T1 (el) Σκευασματα για βενζιμιδαζολυλ πυριδυλ αιθερες
RU2001128071A (ru) Фармацевтическая композиция
NO20073339L (no) Faste formuleringer av flytende biologisk aktive midler
ES2281313T1 (es) Composiciones farmaceuticas que comprenden lercanidipino.
AR054688A1 (es) Alquil-piridinas como inhibidores 11-beta de la diabetes
RU2019126797A (ru) Составы твердых дозированных лекарственных форм антагониста орексинового рецептора
RU2012127776A (ru) Растворимые пленки, содержащие высокие концентрации неионных поверхностно-активных веществ, таких как полисорбаты, для увеличения высоких нагрузок твердых продуктов
RU2017134354A (ru) Фармацевтическая композиция с пролонгированным высвобождением
RU2019133281A (ru) Соединения изоксазолкарбоксамида и их применение
JP6275726B2 (ja) 少なくとも１種の水溶性ビタミンｅ誘導体および少なくとも１種の親水性ポリマーを含む、保存において安定な無塵の均質な粒子製剤
JP2016528196A5 (fr)
KR102066108B1 (ko) 페닐링을 가지는 2종 화합물을 포함하는 화장료 조성물
RU2007128812A (ru) Препараты производных азетидина для инъекций или перорального введения
WO2019240212A1 (fr) Formulation contenant un ingrédient pharmaceutiquement actif
Takekuma et al. Difference in the dissolution behaviors of tablets containing polyvinylpolypyrrolidone (PVPP) depending on pharmaceutical formulation after storage under high temperature and humid conditions
RU2017134106A (ru) Стабильные фармацевтические композиции, включающие антибактериальный реагент
AR067447A1 (es) Un procedimiento para preparar una composicion farmaceutica que contiene los proincipios activos glucosamina y meloxicam y el uso de dicha asociacion para el tratamiento de patologias degenerativas osteo-articulares
ES2426486T3 (es) Composición farmacéutica sólida estabilizada de candesartán cilexetilo
Mimura Crystal and Stability Properties of Clathrates for Drug Substances, and Application of Isothermal Microcalorimetry to Stability Studies

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20140609